"The acquisition of ChemoCentryx represents a compelling opportunity for Amgen to add to our decades-long leadership in inflammation and nephrology with TAVNEOS, a transformative, first-in-class ...

THOUSAND OAKS, Calif., June 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA ® (tarlatamab-dlle) reduced the ...

Amgen said it has started two critical late-stage trials for its experimental weight loss injection, MariTide, another step in its bid to enter the booming obesity drug market. MariTide is a monthly ...

CX-904 was the first masked T-cell engager CytomX Therapeutics took into the clinic. (stocknshares/iStock/Getty Images Plus) Amgen and CytomX Therapeutics have kicked ...

Visit a quote page and your recently viewed tickers will be displayed here.

Amgen has agreed to acquire ChemoCentryx for approximately $3.7 billion, the companies said today, in a deal that expands the buyer’s autoimmune portfolio with an approved drug and two clinical phase ...

Towards the end of January this year, I upgraded my rating on Amgen Inc. (AMGN) stock from a Hold (issued in a note from February 2025) to a Buy, noting that the Thousand Oaks, California-based pharma ...

US market availability for Tavneos continues as Amgen works with the FDA to address concerns over trial data assessment and known hepatotoxicity risks. Amgen is providing prescribers with updated ...

The stock of pharma giant Amgen Inc. (AMGN) is down >10% in early trading today, with shares priced at ~$405 and market cap valuation standing at ~$213bn, as the market digests the news shared last ...

港股首頁 恒指 恒生科技指數 最活躍股票排行 最大升幅股票排行 最大跌幅股票排行 ...

Amgen (AMGN) stock toppled Friday as investors digested its "generally in-line" first-quarter report and aggressive expansion in the obesity treatment space. The company is currently running nine ...

June 12 (Reuters) - Amgen (AMGN.O), opens new tab subsidiary Teneobio must ‌pay biotech company Harbour Antibodies $20.2 million in damages for infringing a patent related to antibodies used in ...